Press2022-05-19T16:29:38-04:00

News & Events

ISSCR Annual Meeting

June 15-18, 2022, Moscone West Convention Center in San Francisco

June 15, 8:30 a.m. PT / 11:30 a.m. PT (available on the virtual meeting platform) – Dr. Murat Kalayoglu, President and Chief Executive Officer, participates as a panelist in Maryland Stem Cell Research Fund Focus Session, “Accelerating Cures – Translating Stem Cell Discoveries into Therapies.” In this Focus session, Maryland-based leaders in the field explore the latest breakthroughs and advances in stem cell disease modeling and tissue engineering approaches. Hear from Dr. Kalayoglu on creating, manufacturing and delivering cell therapies to patients with unmet medical needs.

mRNA-Based Therapeutics Summit

July 26-28, 2022, Hilton Boston

July 28, 12:00 p.m. ET – Dr. Metin Kurtoglu, Chief Operating Officer, participates in the Unleashing the Power of mRNA Technology for CAR-T Therapies session, a presentation titled “Cell Therapy: In & Beyond Oncology.” Dr. Kurtoglu will discuss cell products engineered with RNA that express Chimeric Antigen Receptor (CAR) being tested in autoimmune disease and frontline oncology indications and the potential of RNA Cell Therapies as there is no limit to the number of cells that can be transfected with multiple RNAs and therapeutic functions.

July 28, 4:25 p.m. ET – Dr. Milos Miljkovic, Chief Medical Officer, participates in the Achieving a Successful Route to Equitable Distribution for mRNA-Based Therapeutics & Vaccines session and will lead a presentation titled “Achieving Equitable Access to CAR-T & Other Cellular Therapy Through RNA Engineering.” Dr. Miljkovic will focus on the advantages of RNA-engineered cellular therapy over DNA-based cell therapy. He will also discuss how Cartesian Therapeutics has successfully used three different mRNA-engineered cell therapy products in community clinics around the U.S., and the potential of RNA to make global distribution of effective clinical therapies more equitable.

Antibody Engineering & Therapeutics Europe

June 9, 2022, Postillion Hotel Amsterdam; Digital Experience: All Sessions Livestreamed June 7 – 9

June 9, 2022, 16:55 CET (10:55 a.m. ET) – Dr. Michael Singer presents at Informa’s Antibody Engineering & Therapeutics Conference in a session titled “RNA-Engineered Cell Therapies for Autoimmune Disease.” RNA cell therapies combine the potency of DNA-engineering (such as CAR T-cells) with the speed and manufacturability of RNA. RNA offers another key advantage: controllable pharmacokinetics. In our clinical trials, RNA cell therapies have been remarkably safe. We have administered them in outpatient clinics, with no need for preconditioning chemotherapy. This benefit:risk profile has allowed us to develop therapies for autoimmune disease, including Descartes-08, an anti-BCMA CAR T-cell, for autoantibody-mediated diseases like myasthenia gravis.

Maryland Tech Council Industry Awards

May 12, 2022, Bethesda North Marriott Hotel & Conference Center

May 12, 5:30 p.m. ET – Cartesian has been selected as a finalist for the Emerging Life Sciences Company of the Year award for the Maryland Tech Council’s Industry Awards Celebration. The Industry Awards Celebration hosts attendees from the life sciences and technology industries and is Maryland’s largest and most prestigious award ceremony of its kind.

14th MGFA International Conference On Myasthenia And Related Disorders

May 10-12, 2022, Hyatt Regency Miami

May 10, 10:50 a.m. ET – Dr. Volkan Granit, Neurologist at the University of Miami Health System, will present clinical research of Cartesian’s first CAR T-cell therapy for the treatment of generalized myasthenia gravis (GMG). Descartes-08 contains autologous CD8+ T-cells engineered with RNA chimeric antigen receptors (CARs) that bind B-cell maturation antigen (BCMA). BCMA is expressed ubiquitously by plasma cell clones that produce pathogenic autoantibodies. Descartes-08 binds and kills these cells, eliminating the autoantibody source.

May 10, 6:00 p.m. ET – Cartesian will present a poster on clinical research from its Phase 1a/2a study for Descartes-08 in patients with generalized Myasthenia Gravis. Patients were treated with increasing doses to determine the safety and preliminary efficacy.

Advanced Therapies Week

January 25-28, 2022, Miami Beach Convention Center

Jan. 27, 2:05 p.m. ET – Dr. Metin Kurtoglu, Chief Operating Officer, participates in a session titled “Delivery Solutions and Alternatives for Gene and Cell Therapy,” with a specific emphasis on RNA Cell Therapy in And Beyond Oncology.

Jan. 28, 11:05 a.m. ET – Dr. Emily English, Director of Quality, participates in a session titled “Achieving Best Practice in Quality Control and Assurance,” with a focus on providing an overview of our experience building and evolving quality management systems in an early-stage cell therapy company.

2022 Virtual Advocacy Summit

January 20, 2022

9:00 a.m. ET – Dr. Murat Kalayoglu joins John Stanford, Executive Director at Incubate, in a fireside chat titled “Protecting Innovation: Putting Patients First.” The Maryland Tech Council’s Advocacy Summit will bring industry leaders together to build meaningful relationships with elected officials, provide information about policies that can transform millions of lives and tips on how your advocacy with policymakers in Annapolis can make a difference.

Opportunities for Growth: Biotech Land Use Update

October 22, 2021

Dr. Murat Kalayoglu is joined by other Montgomery County owners and developers, discussing how best to foster the lab space and talent in the area. The discussion focused on nurturing and leveraging the resources of Montgomery County to retain and expand the biotech industry, as well as other growth opportunities in the County.

Bio Innovation Conference

October 5, 2021

9:00 a.m. – Dr. Michael Singer participates in a panel titled “Engineered Cell Therapies: Increasingly Complex Product Development.” In this panel, Dr. Singer will explore how Cartesian is developing innovative approaches for novel cell therapeutics for the treatment of a growing list of intractable diseases. The presentation will be followed by a short Q&A session with the panelists.

11:00 a.m. – Dr. Murat Kalayoglu moderates a panel titled “Cell and Gene Therapy: Beyond Oncology.” The panel discusses the applications of cell therapy beyond the treatment of advanced cancers. Specific examples include the use of cell & gene therapy for the treatment of autoimmune disorders such as myasthenia gravis, respiratory diseases such as ARDS and COVID-19, and rare genetic disorders such as XMEN disease. Ex-vivo cell modification strategies are compared between different approaches and disease indications. Potential benefits of these novel approaches are weighed against treatment risks and costs.

CAR-TCR Summit

September 2, 2021

12:00 p.m. – Dr. Murat Kalayoglu provides a corporate presentation and participates in a Q&A session focused on deploying the company’s RNA Armory® platform to equip cell immunotherapies beyond oncology. He discusses the biological basis and cell therapy engineering approaches to combat respiratory and autoimmune disorders, shares experiences in developing a cGMP manufacturing facility in-house for RNA-based cell therapies, highlights the distinct advantages of an RNA-based engineering platform to targetcells to diseased tissues to deliver any combination of therapies, and provides updates on phase I/II clinical trials for investigational therapies in multiple myeloma, myasthenia gravis, and acute respiratory distress syndrome linked to COVID-19.

2:00 p.m. – Dr. Murat Kalayoglu participates in a panel reflecting on historic developments in the industry, and the ‘why’ behind CAR-TCR’s launch into oncology and discussing the relative advantages and challenges of expanding these technologies to indications beyond oncology.

Maryland Tech Council Industry Awards Celebration

May 20, 2021

Cartesian has been selected as a finalist of the “Emerging Life Sciences Company of the Year” and Dr. Murat Kalayoglu has been selected as a finalist for the “Chief Executive Officer of the Year – Life Sciences” by the Maryland Tech Council. The winners of the awards will be announced at the Industry Awards Celebration on May 20. The event celebrates individuals and companies in the government contracting, life sciences and technology industries that have made a significant impact in their respective industry.

GEN Panel: Manufacturing CAR-T Therapies

March 24, 2021

In this panel, Dr. Metin Kurtoglu, Cartesian’s Chief Medical Officer, speaks to Cartesian’s expertise in manufacturing and characterizing the function and potency of CAR-T cell products using its wholly-owned, state-of-the-art GMP manufacturing facility.

American Association of Neuromuscular & Electrodiagnostic Medicine Spring Virtual Conference

March 2- March 5, 2021

Dr. Kelly Gwanthemey, Assistant Prof of Neurology at Virginia Commonwealth University, presents on emerging therapeutics in myasthenia gravis, including Cartesian’s work with an mRNA cell therapy, Descartes-08.

Sixth Annual 2020 BioHealth Capital Region Virtual Forum

October 19, 2020

Dr. Murat Kalayoglu, President & CEO at Cartesian Therapeutics, participated in a panel titled, “Strengths of the Regions – Cutting Edge Therapies.” The panel brought together leaders from three companies to discuss their disruptive pipelines, the strength of the region and challenges brought by the COVID-19 pandemic.

“Doing Business in the USA,” Maryland Tech Council, Capital M ZoomCast Live – International Special Edition

September 16, 2020

Dr. Murat Kalayoglu, President & CEO at Cartesian Therapeutics, joins a panel hosted by Martin Rosendale, CEO of the Maryland Tech Council. On this CapitalM ZoomCast Live event Dr. Kalayoglu discusses Cartesian and its role in the Maryland science eco-system.

Date Outlet Type Title
May 17, 2022 Myasthenia Gravis News Article CAR T-cell Therapy Descartes-08 Continues to Show Promise in Trial
May 13, 2022 BioCentury Article Cartesian expanding therapeutic window, disease settings for CAR T
May 13, 2022 Maryland Tech Council Award Maryland Tech Council Unveils Winners of 34th Annual Industry Awards
May 10, 2022 Cell & Gene Therapy Insights Article Unleashing the full potential of cell therapy through RNA engineering
April 28, 2022 Washington Business Journal Article Companies to watch: 6 life sciences leaders see Montgomery County as partner in success
April 12, 2022 BioTuesdays Article In conversation with Dr. Murat Kalayoglu of Cartesian
April 2, 2022 BioSpectrum Asia Article Exploring the Possibilities of RNA Therapeutics
March 7, 2022 Science Line Article The mRNA revolution is just getting started
March 7, 2022 The Daily Record Article Md. Tech Council announces 2022 Industry Awards finalists
February 28, 2022 CGT Live Article Advancing Treatments for Rare Diseases Requires a Team Approach
January 7, 2022 BioSpace Article Cartesian Aims to Propel RNA Cell Therapy with Combinations
January 6, 2022 Cell & Gene Podcast RNA’s Advantages Over Other Cell Therapies With Cartesian’s CSO
January 4, 2022 Biopharma Reporter Article Cartesian Therapeutics: Senior Advisors
December 1, 2021 PharmaShots Article PharmaShots Interview: Cartesian Therapeutics’s Dr. Murat Kalayoglu Shares Insight on RNA Cell Therapy for an Autoimmune Disease
November 30, 2021 Washington Business Journal Article Gaithersburg is evolving gradually, with several new projects in the works. Join us on a tour.
November 29, 2021 Technology Networks Article Innovating Reversible Cell Therapies With RNA
November 9, 2021 Pharmaceutical Executive Article The New COVID Workforce: Keeping Pharma Strong Through Adversity
November 5, 2021 DNAweekly Article Exploring RNA-Based Oncology Treatments With Cartesian Therapeutics
October 18, 2021 BioSpace Article Carting Away Problematic Cells with CAR-T Therapy for Myasthenia Gravis
October 5, 2021 GEN Article Building a Bioprocess for RNA-Based Therapies
October 1, 2021 Fierce Biotech Brief Chutes & Ladders—FDA’s vaccine office gets new leader as 2 officials head toward exit
September 30, 2021 BioSpace Brief BioSpace Movers & Shakers, Oct. 1
September 29, 2021 PharmTech Focus Article Cartesian Therapeutics Strengthens Leadership Team With Hire of Miloš Miljković, M.D., as Chief Medical Officer
September 28, 2021 Washington Business Journal Article Gaithersburg biopharma prepares to double footprint, headcount
September 28, 2021 BioWorld Brief Appointments and advancements for Sept. 28, 2021
September 10, 2021 Gene Therapy Live Video RNA-Modified vs DNA-Modified CAR T Products
September 9, 2021 Myasthenia Gravis News Article CAR T-cell Therapy Descartes-08 Eased MG Symptoms
August 18, 2021 Cell & Gene Podcast State-of-the-Art GMP Manufacturing RNA Cell Therapies With Cartesian’s CEO
August 16, 2021 Life Science Leader Article Implementing GMP For Early-Phase Development With Cartesian Therapeutics Co-Founder And CEO, Dr. Murat Kalayoglu
July 22, 2021 Clinical Leader Article No CMOs Or CROs: A Unique Approach To Cell Therapy Development
July 9, 2021 RARECAST Podcast Episode #342 – Overcoming the Limitations of Conventional Cell Engineering
June 30, 2021 BioProcess Online Article GMP Manufacturing Of RNA-Engineered Cell Therapies
June 28, 2021 BioTalk Podcast Murat Kalayoglu, MD, PhD – Cartesian Therapeutics (EP.89)
June 28, 2021 Clinical Trials Arena Article Cartesian: pioneering RNA-engineered cell therapy in cancer and beyond
June 13, 2021 Contagion Live Article + Video RNA Cell Therapy for COVID-19 Related ARDS in Development
June 7, 2021 Business of Biotech Podcast RNA-Engineered Cell Therapy With Cartesian’s Dr. Murat Kalayoglu
June 2, 2021 Cell & Gene Article RNA Cell Therapy: A New Class of Advanced Therapies
May 3, 2021 Health Professional Radio Podcast Cartesian-Therapeutics-–-Pioneering-mRNA-Engineered-Cell-Therapy
April 27, 2021 Healio Article The case for CAR T cells as earlier treatment requires more evidence
March 24, 2021 GEN Panel CAR-T Therapy: Working with a Manufacturing Partner
March 17, 2021 Informa Panel Pandemic Perspectives: R&D Lessons Learned from the COVID Year
March 11, 2021 DocWire News Video Interview Dr. Murat Kalayoglu Discusses New Frontline Therapy Treatment for Multiple Myeloma
March 8, 2021 OncLive Article mRNA-Based CAR T-Cell Therapy Descartes-11 Moves Into Phase 2 Trial in Myeloma
March 5, 2021 Cancer Therapy Advisor Article Descartes-11 Trial Tests RNA-Engineer Cell Therapy in Multiple Myeloma
February 26, 2021 Precision Oncology News Article Cartesian Therapeutics Bets on mRNA Engineering for Moving CAR T Cells Into Frontline Treatment
February 25, 2021 CURE Article CURE’s Clinical Trial Corner: February 2021
Go to Top